Skip to content

Ibogaine: all studies

Page 8 of 61: studies 71 to 80 of 610, newest first. Back to the ibogaine overview

Research

Pain Relief: Unique Derivatives of Ibogaine Alleviate Both Acute and Chronic Pain Symptoms

Physiology May 1, 2024 Sanjit Dey, Tuhin Bhattacharya, Surajit Sinha 1 citation

Pain induction results in the initiation of neuroinflammatory and neurodegenerative processes, leading to neuromodulation, while conventional analgesic treatments frequently entail undesirable side effects. This research delves into the potent and selective analgesic attributes of Iboga derivatives in the context of acute and chronic pain models. Specifically, the study explores the effcacy of...

DOI: 10.1152/physiol.2024.39.s1.1689 (opens in new tab) Chronic pain Acute pain Pain relief Intensive care medicine +2

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Journal of Psychopharmacology May 1, 2024 Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al. 15 citations

Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...

Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine

American Journal of Therapeutics March 1, 2024 Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al. 9 citations

BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury....

Magnesium-ibogaine therapy in veterans with traumatic brain injuries.

Nature Medicine February 1, 2024 Kirsten Cherian, Jackob N. Keynan, Lauren Anker et al. 66 citations

Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a...

DOI: 10.1038/s41591-023-02705-w (opens in new tab) Full text (opens in new tab) Tbi treatment Brain injury recovery Tbi intervention Head injury treatment +17

A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets.

Translational Psychiatry January 19, 2024 Judit Biosca-Brull, Genís Ona, Lineth Alarcón-franco et al. 5 citations

Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the mechanisms that may underlie its anti-addictive effects are still not defined. This study aims to identify changes in gene expression induced by a single oral dose of IBO in the cortex of mice by means of a transcriptomic analysis for the first time. Our results showed significant alterations in gene...

5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.

International Journal of Molecular Sciences January 5, 2024 Sofía Villalba, Bruno González, Stephanie Junge et al. 9 citations

Noribogaine (noribo) is the primary metabolite from ibogaine, an atypical psychedelic alkaloid isolated from the root bark of the African shrub Tabernanthe iboga. The main objective of this study was to test the hypothesis that molecular, electrophysiological, and behavioral responses of noribo are mediated by the 5-HT2A receptor (5-HT2AR) in mice. In that regard, we used male and female,...

Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis.

Journal of Psychoactive Drugs 2024 Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al. 7 citations

Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe...

The Nonclassic Psychedelic Ibogaine Disrupts Cognitive Maps.

Biological Psychiatry Global Open Science 2024 Victorita E. Ivan, David P Tomàs-Cuesta, Ingrid M. Esteves et al. 7 citations

The ability of psychedelic compounds to profoundly alter mental function has been long known, but the underlying changes in cellular-level information encoding remain poorly understood. We used two-photon microscopy to record from the retrosplenial cortex in head-fixed mice running on a treadmill before and after injection of the nonclassic psychedelic ibogaine (40 mg/kg intraperitoneally). We...

Ibogaine administration following repeated morphine administration upregulates myelination markers 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats.

Frontiers in Neuroscience 2024 Demi Govender, Leila Moloko, Maria Papathanasopoulos et al. 10 citations

Ibogaine is a psychedelic alkaloid being investigated as a possible treatment for opioid use disorder. Ibogaine has a multi-receptor profile with affinities for mu and kappa opioid as well as NMDA receptors amongst others. Due to the sparsity of research into ibogaine's effects on white matter integrity and given the growing evidence that opioid use disorder is characterized by white matter...

DOI: 10.3389/fnins.2024.1378841 (opens in new tab) Full text (opens in new tab) Opioid use disorder Oligodendrocytes Psychedelic medicine ibogaine Psychedelic drug +10

Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.

Journal of Addictive Diseases 2024 Alexandra Arenson, Cynthia I Campbell, Ilan Remler 8 citations

The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...